Anaplastic Large Cell Lymphoma (systemic) · line 2 · Brentuximab vedotin monotherapy (1.8 mg/kg IV q3 weeks × up to 16 cycles) for r/r systemic ALCL
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Line of therapy | 2 |
|---|---|
| Track | standard |
| Linked regimen | REG-BV-MONO-SYSTEMIC-ALCL |
| ID | IND-ALCL-2L-BRENTUXIMAB-MONO |
|---|---|
| Type | Indication |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-ALCL |
| Sources | SRC-ESMO-LYMPHOMA-2025 SRC-NCCN-BCELL-2025 |
Notes
STUB — pending Clinical Co-Lead sign-off. Standard-track 2L+ for r/r systemic ALCL (both ALK+ and ALK-). Bridge to alloSCT consolidation in fit responders is practice standard. Funding gap in UA — fundraising pathway often required.
Used By
Algorithms
ALGO-ALCL-2L- ALGO-ALCL-2L